Evommune launches mid-stage trials for immune-modulating drugs targeting skin conditions, backed by $115M funding and led by ex-Dermira executives.

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

Psoriasis shows on the skin, but it's a disease which goes a lot deeper and is linked to serious health problems. In recent years, newer targeted drugs are making a difference.

Ultrasound-detected dactylitis lesions may help identify patients with psoriasis who are at risk for psoriatic arthritis and ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

For example, the small-molecule inhibitor zasocitinib (formerly TAK-279) produced a PASI 75 response rate of 67-68% after 12 ...

times greater than the prevalence in patients without psoriasis, according to the meta-analysis. Among several limitations, moderate to high heterogeneity is observed and some studies have small ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

SBA 7(a) loans are the most common type of SBA loan and can be used for a variety of purposes. They’re a good option for long-term financing and have maximum loan limits of up to $5 million.

2 With the growing availability of biosimilars for moderate to severe psoriasis, it remains unclear whether those ... with slight improvements or worsening occurring in a small percentage of patients.